Drugs / Myrcludex B
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02637999 | Feb 2014 → Jan 2016 | hepatitis D virus infection | Hepatera Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT02881008 | Nov 2012 → Oct 2014 | chronic hepatitis B virus infection | Hepatera Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02888106 | Apr 2016 → Nov 2019 | chronic hepatitis B virus infection | Hepatera Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03546621 | Feb 2016 → Jan 2018 | hepatitis D virus infection | Hepatera Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Myrcludex B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02637999 ↗ |
| Known as | Hepcludex | “SU is co-applicant and co-inventor on patents protecting Hepcludex (Bulevirtide/Hepcludex) and consultant for Gilead Sciences.” PMID 37120031 ↗ Apr 2023 |
| Action | Inhibit | “Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.” PMID 38340811 ↗ Feb 2024 |
| Modality | Peptide | “Bulevirtide is a first-in-class peptidic entry inhibitor for hepatitis B virus (HBV) and hepatitis D virus infection.” PMID 36113537 ↗ Sep 2022 |
| Route | Subcutaneous | “Myrcludex B 0.5 mg / day / sc / 12 weeks” NCT02881008 ↗ |